相关实验视频
Updated: Jun 20, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
增强的二硫化键稳定性有助于胰岛素的每周一次的表达
František Hubálek1, Christian N Cramer2, Hans Helleberg2
1Novo Nordisk A/S, Maaloev, Denmark. FHUB@novonordisk.com.
Nature communications
|July 20, 2024
概括
胰岛素的编码 (icodec)
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 胰岛素icodec是一种新的基础胰岛素类似物,旨在每周一次给药.
- 它的开发旨在通过降低受体亲和力和增强蛋白结合来实现长期的药理动力学/药理动力学特征.
- 了解胰岛素清除机制对于优化长效胰岛素配方至关重要.
研究的目的:
- 为了研究胰岛素清除背后的分子机制.
- 为了确定在胰岛素降解中硫化-硫化交换反应的作用.
- 为了评估胰岛素icodec对这些降解通路的稳定性.
主要方法:
- 从小猪和2型糖尿病患者的血样本中分析胰岛素降解.
- 作为胰岛素清除途径,研究硫化-硫化交换反应.
- 通过生物化学测定评估胰岛素icodec稳定性.
主要成果:
- 鉴定出二硫化物交换反应是胰岛素清除的重要机制,导致A链和B链分裂.
- 由于特定的分子替代,胰岛素icodec对这种降解途径表现出增强的稳定性.
- 尽管稳定,但在血样本中检测到了一些自由的B链,这表明残留的敏感性.
结论:
- 硫化-硫化交换是胰岛素清除的关键途径.
- 胰岛素对这种反应的稳定是导致其长半衰期和适合每周服用一次的重要因素.
- 进一步的研究可能会完善稳定策略,甚至更长效的胰岛素类似物.
相关概念视频
Protein and Protein Structure
79.3K
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme...
A protein's shape is critical to its function. For example, an enzyme...
79.3K
Insulin: Biosynthesis, Chemistry, and Preparation
369
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
369
Insulin Formulations: Types and Delivery
182
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
182
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180

